Continuous Glucose Monitoring Technology and Insulin Dosing: What Pharmacists Need to Know

Continuous Glucose Monitoring Technology and Insulin Dosing: What Pharmacists Need to Know

On-Demand Webcast

This webcast is based on live proceedings from a symposium conducted at the APhA2017.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.


Nancy J. D'Hondt, RPh, CDE, FAADE
Clinical Pharmacist
St. John Providence Hospital and Medical Center
Detroit, Michigan
American Association of Diabetes Educators

Stephanie Smith, PharmD, CDE
Medication Therapy Management Pharmacist
Certified Diabetes Educator
Ridgeview Endocrinology Clinic
Chaska, Minnesota

Intended Learners

This activity is designed for practicing pharmacists, pharmaceutical scientists, and student pharmacists.

Learning Objectives

After completing this activity, participants should be able to:

  • Identify patients with diabetes who may be candidates for continuous glucose monitoring, such as those with increased risk of severe hypoglycemia or on intensive insulin therapy
  • Describe the limitations of self-management of blood glucose and impact on accurate and informed dosing and diabetes management decisions
  • Differentiate among available continuous glucose monitors (CGMs) in terms of technical features, benefits and limitations, accuracy, device compatibility and integration, data sharing, ease of use, and data supporting dosing decisions
  • Integrate relevant real time and retrospective CGM data and device information into pharmacy practice and management decisions including CGM patient education and counseling programs and health care team communication
Activity Overview

This on-demand webcast was recorded from the live APhA2017 breakfast symposium on March 26, 2017. 

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10 question post-test with a score of 70% or better, and complete the evaluation form.

After successful completion of the post-test and evaluation form online at, participants may immediately print their documentation of credit.

ACPE Credit Policy

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. The reporting function into CPE Monitor will only be available for 60 days after your completion of the activity.  Under ACPE Policy, NACCME will not be able to report your credit to CPE Monitor after this 60 day period.

Release Date: March 31, 2017
Expiration Date: March 31, 2018
Estimated time to complete: 1.25 hours

Participants who completed the live version of this activity are not eligible to receive credit for this enduring material.

For questions regarding this educational activity, please call 609-371-1137.

There is no fee associated with this activity.

Hardware/Software Requirements

All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested for video programs (please download here). A PDF reader is required for print publications. Please direct technical questions to


   In support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.




This enduring activity is approved for 1.25 contact hours (.15 CEUs) of continuing pharmacy education (UAN 0276-0000-17-093-H01-P).

This educational activity is a knowledge-based activity.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Senior Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, Suite 200, East Windsor, NJ 08520. The Senior Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Independent Clinical Reviewer: Kyle R. Copeland, PharmD, Clinical Specialist Pharmacist, Parkwest Medical Center, Assistant Professor, University of Tennessee College of Pharmacy, Knoxville, Tennessee

Planning Committee

The planning committee comprises Kyle R. Copeland, Nancy D'Hondt, RPh, CDE, FAADE, Stephanie Smith, PharmD; and Donna Brophy, Mary Johnson, Kristin Ciszeski, Michelle Montgomery, Randy Robbin, John Savage, and Sydney Turner, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Smith: Speakers' Bureau—AstraZeneca, Dexcom, Inc, Janssen, Novo Nordisk, Sanofi

Dr. Copeland and Ms. D'Hondt have disclosed no relevant financial relationships with any commercial interest.

Ms. Brophy, Ms. Johnson, Ms. Ciszeski, Mr. Robbin, Mr. Savage, and Ms. Turner have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty have disclosed that the use of Abbott Freestyle Libre, liraglutide for type 1 diabetes mellitus, and continuous glucose monitoring in hospitalized patients will be discussed.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2017 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

This activity has been supported through an independent educational grant from Dexcom, Inc.